Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Nuchev Pty Ltd Business Overview & Revenue Model
Nuchev Pty Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.89M | 22.94M | 11.34M | 8.79M | 9.72M | 10.90M |
| Gross Profit | 5.53M | 10.86M | 3.63M | 1.90M | 2.78M | 3.20M |
| EBITDA | -2.00M | -3.73M | -7.18M | -8.57M | -10.88M | -12.40M |
| Net Income | -2.24M | -3.82M | -7.32M | -8.81M | -11.11M | -13.27M |
Balance Sheet | ||||||
| Total Assets | 17.39M | 17.39M | 20.09M | 15.32M | 17.75M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 3.61M | 3.61M | 7.61M | 7.49M | 5.13M | 14.53M |
| Total Debt | 392.63K | 392.63K | 322.85K | 284.14K | 154.12K | 286.33K |
| Total Liabilities | 6.16M | 6.16M | 5.34M | 2.51M | 1.92M | 1.62M |
| Stockholders Equity | 11.23M | 11.23M | 14.75M | 12.82M | 15.83M | 26.69M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -3.93M | -3.74M | -3.38M | -11.62M | -9.86M |
| Operating Cash Flow | -1.20M | -3.74M | -3.73M | -3.26M | -11.61M | -9.49M |
| Investing Cash Flow | -92.51K | -138.16K | -2.19M | -126.83K | -914.20K | 411.90K |
| Financing Cash Flow | -51.40K | -115.53K | 6.06M | 5.78M | -118.28K | 14.16M |
Nuchev Pty Ltd Technical Analysis
Nuchev Pty Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
| ― | AU$27.27M | -1.37 | -31.14% | ― | -15.07% | 29.50% | |
| ― | AU$20.23M | 5.77 | -29.43% | ― | 102.21% | 69.47% | |
| ― | €16.79M | -0.47 | -184.71% | ― | 39.53% | 49.99% | |
| ― | AU$36.02M | ― | ― | ― | 1.03% | -52.56% | |
| ― | AU$28.99M | ― | -20.54% | ― | 13.92% | 36.28% |
Nuchev Pty Ltd Corporate Events
Nuchev Limited announced the issuance of 917,467 unquoted securities under an employee incentive scheme, which are subject to transfer restrictions and will not be quoted on the ASX until these restrictions are lifted. This move is part of the company’s strategy to incentivize its workforce, potentially impacting its operational dynamics and aligning employee interests with long-term company performance.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited, a company listed on the ASX under the code NUC, has released its 2025 Corporate Governance Statement, emphasizing its commitment to high standards of corporate governance. The company adheres to the ASX Corporate Governance Principles and Recommendations, ensuring transparency, fair dealing, and stakeholder protection. The statement outlines the company’s governance practices and compliance with the ASX guidelines, highlighting areas where recommendations were not followed and the alternative practices adopted. This approach aims to maintain stakeholder trust and ensure legal compliance.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd has released its 2025 Annual Report, emphasizing its vision to become a global leader as a House of Brands focused on transforming wellness, longevity, and quality of life through therapeutic, future-focused solutions. The report outlines the company’s commitment to inspiring healthier and happier futures, with a focus on risk and governance, directors’ and remuneration reports, and financial statements, indicating a strategic approach to enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the notice of its 2025 Annual General Meeting, which will be held virtually on November 28, 2025. This meeting is significant for shareholders as it affects their shareholding and voting rights. The company continues to emphasize its commitment to providing high-quality nutritional and wellness products, reflecting its strategic positioning in the industry.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd reported a 30% increase in group revenue to $6.5 million for Q1 FY26, driven by strong sales in the ANZ region and successful market entry into Vietnam. The company’s Oli6® Nutritional sales showed significant growth, particularly in China and Vietnam, underscoring the brand’s market strength and strategic distribution partnerships. Despite cash flow challenges due to production costs and timing, Nuchev remains focused on profitability and market expansion through new product development and strategic agreements.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has secured a $2 million unsecured Working Capital Facility funded by two substantial shareholders. This facility will enable the company to expedite its growth plans, providing flexibility to explore further expansion opportunities and aim for positive cash flows and profitability in the short to medium term.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced a change in its shareholder registry services provider, transitioning from Automic Pty Ltd to XCEND Pty Ltd. This change will take effect after market close on October 24, 2025. The move is part of the company’s ongoing efforts to streamline operations and enhance service delivery to stakeholders.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the date for its 2025 Annual General Meeting (AGM), which will take place on November 28, 2025. The deadline for director nominations is set for October 17, 2025. This announcement is part of the company’s compliance with ASX Listing Rules and its Constitution, and further details will be provided in a separate Notice of Meeting. This scheduling is crucial for stakeholders as it defines the timeline for potential leadership changes and strategic planning.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd reported a significant revenue increase of 110% for the fiscal year ending June 2025, driven by strong sales in nutritional and dietary supplements. The company improved its net contribution margin and reduced its operating loss, signaling progress towards profitability. Strategic moves, including the acquisition of bWellness and expansion into new markets, have strengthened its market position. The company ended the year with a positive cash position and no external debt, indicating robust financial health.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has released its financial report for the year ending 30 June 2025. The report includes various financial statements and declarations, providing a comprehensive overview of the company’s financial performance and position. This release is crucial for stakeholders as it offers insights into the company’s profitability, financial health, and operational efficiency, which are essential for assessing future prospects and making informed investment decisions.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited reported a significant increase in revenue from ordinary activities, rising by 102.2% to $22.9 million for the year ended 30 June 2025. Despite this growth, the company still reported a loss of $3.8 million, although this represents a 47.7% improvement compared to the previous year. The company did not pay or declare any dividends during the current or previous financial periods, and it lost control over several entities, including Nanny Grove Pty Ltd and Nuchev Property Pty Ltd, during the year.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has issued 8,749,000 fully paid ordinary shares without disclosure to investors, in compliance with the Corporations Act 2001. The company confirms adherence to its reporting and disclosure obligations, with no excluded information requiring disclosure. This move reflects Nuchev’s ongoing commitment to transparency and regulatory compliance, potentially impacting its market operations and stakeholder confidence.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.